Drug Profile

Atebimetinib - Immuneering

Alternative Names: IMM-1-104

Latest Information Update: 30 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Immuneering
Class Antineoplastics; Small molecules
Mechanism of Action Mitogen-activated protein kinase kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pancreatic cancer
New Molecular Entity Yes

Highest Development Phases

Phase I/II Solid tumours

Most Recent Events

24 Sep 2025 Efficacy and adverse events data from a phase I/IIa trial in Solid tumours released by Immuneering Corporation
25 Aug 2025 Immuneering Corporation entered into a clinical supply agreement with Eli Lilly and Company for olomorasib
25 Aug 2025 Immuneering plans a phase II trial for Non-small cell lung cancer (Combination therapy, Second-line or greater therapy, Metastatic disease)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com